ABBV - AbbVie: 5 Reasons That Make A Buy Case

2024-06-18 17:37:24 ET

Summary

• AbbVie's weak stock price performance in the past quarter is in no way an indication of the progress it has made in recent months.
• Turnaround in revenue growth following Humira's patent expiration is now evident and recent acquisitions could bolster growth further.
• EPS trends have improved too, while a stable operating income is also encouraging.
• The market multiples assessed in three ways are also more attractive than not, and the dividend yield isn't bad either.

Since I last wrote about the pharmaceuticals company AbbVie Inc. ( ABBV ) in March, its stock market performance has been underwhelming, with a 3% price decline. This isn't an entirely surprising short-term movement....

For further details see: